Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabidiol-based therapeutics - Neuropathix

Next Previous
Drug Profile

Research programme: cannabidiol-based therapeutics - Neuropathix

Alternative Names: Cannabinoid-based antioxidants - Neuropathix; Cannabinoid-based neuroprotectants - Neuropathix

Latest Information Update: 28 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KannaLife Sciences
  • Developer Neuropathix
  • Class Anti-inflammatories; Benzene derivatives; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Brain injuries

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for preclinical development in Brain injuries in USA
  • 31 Dec 2021 Neuropathix has patents pending, patends abandone, patents expired and patents issued for inflammation, pain radiation dermatitis, skin disorders, hepatic encephalopathy in US, Japan, China, Belgium, Denamrk, Germany, in Ireland, Italy, in the Netherlands, in Spain, in Switzerland, France, in Turkery, in the UK, Europe, Macao, Australia, India, Russia Canada as of December 2021
  • 19 Jun 2020 Kannalife plans to submit NDA for KLS 13023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top